Life Sciences

Serving life sciences companies for more than 25 years, Latham & Watkins represents leading and emerging companies in this broad and rapidly evolving industry.

Why Latham

Strategic Counsel

Life sciences companies worldwide rely on Latham’s unique combination of industry knowledge, legal acumen, and strategic business expertise. Many of the firm’s lawyers hold advanced scientific degrees and have hands-on experience working in life sciences companies or within the government agencies that regulate the industry.

This deep understanding of the global life sciences industry allows Latham's lawyers to offer superior counsel to clients involved in transactions, investigations, litigation, intellectual property matters, and regulatory challenges. They understand the economic, market, regulatory, and political climates in which life sciences companies operate and integrate these factors when addressing clients’ legal and business needs.

Client-focused Representation

Latham represents public and private life sciences companies at all stages of development, from startup and emerging growth to mature public companies, in the following industries:

  • Biofuels
  • Bioinformatics
  • Biotechnology
  • Cosmeceuticals 
  • Diagnostics
  • Drug delivery
  • eHealth
  • Genomics
  • Healthcare
  • Medical devices
  • Nanotechnology
  • Pharmaceuticals
  • Proteomics
  • Therapeutics

In addition, the firm’s lawyers play important roles in the industry, serving as primary outside counsel for the Advanced Medical Technology Association and as primary outside FDA counsel to the Medical Device Manufacturers Association. Latham also is a leader in key life sciences industry organizations including BIO, CLSA, and BIOCOM.

Deep Industry Knowledge

Latham lawyers work closely with life sciences clients to address their legal needs and achieve their goals throughout the full life cycle of their companies. The firm also serves as company counsel in a range of areas, including:

Lawyers in this group assist clients in raising capital in:

The firm’s mergers and acquisitions work in the life sciences industry routinely includes:

Latham’s regulatory and enforcement work in the life sciences industry covers:

And its technology transactions have included:

  • Asset acquisitions
  • Commercial contracts and license agreements
  • Commercialization channel and sales agreements
  • Joint ventures
  • Outsourcing
  • R&D agreements
  • Strategic alliances
  • Supply and manufacturing agreements
  • University licensing

 Finally, Latham provides IP counseling and litigation services in areas such as:

Awards & Rankings

   
  • Latham Again Named Washington, D.C. Intellectual Property Litigation Department of the Year - May 27, 2020
  • San Diego Partner Named Healthcare Trailblazer - April 12, 2020
  • Two Latham Trial Victories Honored Among California’s Top Verdicts - February 26, 2020
  • Washington, D.C. Partner Honored with Pursuit of Justice Award - January 28, 2020
  • Latham Named 2019 Securities Group of the Year - January 15, 2020

Latham offers particular strength in multi-jurisdictional transactions, including M&A and capital markets matters," with "particular activity in the biotechnology and medical devices industries" and "additional capabilities in IP-related disputes." Clients praise the firm's "strong, very good technical lawyers, and they understand the legal principles and the regulatory principles as well."

Chambers Global 2020

Events

FDLI Annual ConferenceWebcast: Recent Developments in Health Care Enforcement

Media Coverage

Federal Circuit, Judge Nix CardioNet Heart Monitor Patent ClaimsLatham Strikes Again on Branded Pharma by Adding 2 LitigatorsDC Circ. Rejects Trump's 'Far-Flung' Drug Pricing Rule

News

Firm Advises Juno Therapeutics in JW Therapeutics’ Series B FinancingLatham Advises Revolution Medicines in its $156 Million Public OfferingLatham & Watkins Advises VillageMD in Partnership with Walgreens

Thought Leadership

COVID-19: Managing Worker Health & Safety Rise in Securities Class Action Filings in Life Sciences SectorHong Kong Stock Exchange Issues New Guidance for Biotech Listings

Webcasts & Podcasts

Podcast – How Does Growth Debt Fuel Start-Ups Between Equity Rounds?IP Strategic Considerations